Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner
11:35pm, Wednesday, 28'th Dec 2022 The Motley Fool
The stock market lost ground as economic worries persist.
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
06:48pm, Wednesday, 28'th Dec 2022 GlobeNewswire Inc.
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the
Pfizer Makes Progress, but This Biotech Was Wednesday's Big Winner
06:35pm, Wednesday, 28'th Dec 2022
The stock market lost ground as economic worries persist.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
06:00pm, Wednesday, 28'th Dec 2022 Benzinga
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal
Stocks To Watch: Nio, Tesla And Hopes For A Santa Clause Rally
03:00pm, Saturday, 24'th Dec 2022 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
06:47pm, Friday, 16'th Dec 2022 Benzinga
Gainers
Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.
Maxar Technologies Inc. (NYSE: MAXR) shares jumped 12
TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024
02:04pm, Thursday, 15'th Dec 2022
TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsing forms of multiple sclerosis (RMS). It appears t
TG Therapeutics: Would Santa Deliver An Early Present?
06:08pm, Wednesday, 14'th Dec 2022
TG Therapeutics, Inc. management has been focusing on the company's most valuable (multiple sclerosis) franchises in an effort to turn around. TG Therapeutics' ublituximab generated extremely strong P
Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?
02:55pm, Friday, 02'nd Dec 2022 Zacks Investment Research
The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
11:01am, Friday, 02'nd Dec 2022 Benzinga
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Th
3 Medical Products Stocks Navigating Industry Challenges (Revised)
11:49am, Thursday, 24'th Nov 2022 Zacks Investment Research
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
3 Medical Products Stocks Navigating Industry Challenges (Revised)
08:17am, Thursday, 24'th Nov 2022
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics
01:48pm, Monday, 21'st Nov 2022 Zacks Investment Research
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
3 Medical Products Stocks Navigating Industry Challenges
12:54pm, Friday, 18'th Nov 2022 Zacks Investment Research
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
3 Medical Products Stocks Navigating Industry Challenges
09:10am, Friday, 18'th Nov 2022
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-pois
